QuickView for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=9A293F9B4FD554D3CFAA1B9898B171E8;jsessionid=C8B5755C1AB667BEC9CC28337B057DA7;jsessionid=C1A62CE3455E97C87B6E5FC8388D846F;jsessionid=FC86B84DEC34730669ACB575536F6B4F;jsessionid=F4F1327503FA1BAFA5B71E55AD27CD1A;jsessionid=7E3070037A1C259599C82C8D4B51EAFB;jsessionid=F72FB9388CC50D063D2F9624AC08638F;jsessionid=2BBAB863D5F9842F6514C1F2C984E927 (gene)

1. Thymic stroma and TFII-I: towards new targeted therapies.
2. Proteomic analysis of SRF associated transcription complexes identified TFII-I as modulator of SRF f…
3. Structural basis for evolutionarily conserved interactions between TFIIS and Paf1C.
4. The TFIIS N-terminal domain (TND): a transcription assembly module at the interface of order and dis…
5. Astragaloside IV attenuates sunitinib-associated cardiotoxicity by inhibiting COUP-TFII.

There were no clinical trials for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=9A293F9B4FD554D3CFAA1B9898B171E8;jsessionid=C8B5755C1AB667BEC9CC28337B057DA7;jsessionid=C1A62CE3455E97C87B6E5FC8388D846F;jsessionid=FC86B84DEC34730669ACB575536F6B4F;jsessionid=F4F1327503FA1BAFA5B71E55AD27CD1A;jsessionid=7E3070037A1C259599C82C8D4B51EAFB;jsessionid=F72FB9388CC50D063D2F9624AC08638F;jsessionid=2BBAB863D5F9842F6514C1F2C984E927